Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Non-Current Assets: 2015-2025

Historic Other Non-Current Assets for Seres Therapeutics (MCRB) over the last 10 years, with Sep 2025 value amounting to $8.7 million.

  • Seres Therapeutics' Other Non-Current Assets fell 12.21% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 12.21%. This contributed to the annual value of $8.7 million for FY2024, which is 86.33% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Other Non-Current Assets is $8.7 million, which was down 0.00% from $8.7 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Other Non-Current Assets peaked at $63.4 million during Q4 2023, and registered a low of $601,000 during Q3 2021.
  • Over the past 3 years, Seres Therapeutics' median Other Non-Current Assets value was $11.3 million (recorded in 2023), while the average stood at $20.5 million.
  • Per our database at Business Quant, Seres Therapeutics' Other Non-Current Assets spiked by 1,819.80% in 2022 and then crashed by 86.33% in 2024.
  • Over the past 5 years, Seres Therapeutics' Other Non-Current Assets (Quarterly) stood at $8.0 million in 2021, then soared by 30.81% to $10.5 million in 2022, then skyrocketed by 505.70% to $63.4 million in 2023, then slumped by 86.33% to $8.7 million in 2024, then fell by 12.21% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q3 2025, $8.7 million for Q2 2025, and $8.7 million during Q1 2025.